Triamcinolone-induced cataract in eyes with diabetic macular oedema: 3-year prospective data from a randomized clinical trial

Authors

  • Mark C Gillies FRANZCO PhD,

    Corresponding author
    1. Department of Clinical Ophthalmology, Save Sight Institute, University of Sydney, Sydney, New South Wales
    Search for more papers by this author
  • Fakir MA Islam PhD,

    1. Centre for Eye Research Australia, University of Melbourne, Melbourne, Victoria
    2. Department of Mathematics and Computing, University of Southern Queensland, Toowoomba, Queensland, Australia
    Search for more papers by this author
  • Jörgen Larsson MD PhD,

    1. Department of Clinical Ophthalmology, Save Sight Institute, University of Sydney, Sydney, New South Wales
    2. Department of Ophthalmology, Lund University Hospital, Lund, Sweden
    Search for more papers by this author
  • Sirichai Pasadhika MD,

    1. Department of Clinical Ophthalmology, Save Sight Institute, University of Sydney, Sydney, New South Wales
    Search for more papers by this author
  • Chris Gaston MBBS,

    1. Department of Clinical Ophthalmology, Save Sight Institute, University of Sydney, Sydney, New South Wales
    Search for more papers by this author
  • Meidong Zhu MBBS PhD,

    1. Department of Clinical Ophthalmology, Save Sight Institute, University of Sydney, Sydney, New South Wales
    Search for more papers by this author
  • Tien Y Wong FRANZCO PhD

    1. Centre for Eye Research Australia, University of Melbourne, Melbourne, Victoria
    2. Singapore Eye Research Institute, Singapore National Eye Centre, Singapore
    Search for more papers by this author

Errata

This article is corrected by:

  1. Errata: Erratum Volume 38, Issue 7, 741, Article first published online: 13 October 2010

Dr Mark C Gillies, Save Sight Institute, University of Sydney, 8 Macquarie Street, Sydney, NSW 2000, Australia. Email: mark@eye.usyd.edu.au

Abstract

Purpose:  To describe the 3-year risk of cataract after intravitreal triamcinolone (IVTA) injections for diabetic macular oedema and the outcomes of cataract surgery.

Methods:  Prospective data from a randomized clinical trial were analysed. At baseline, 27 phakic eyes with diabetic macular oedema were randomized to receive IVTA and 25 to receive sham injection. After 2 years, initial sham-treated eyes were eligible to receive IVTA as the study became open label for the third year. The cumulative incidence of cataract surgery was the primary outcome of the study. Other outcomes assessed included progression of cataract, best-corrected logarithm of the minimal angle of resolution visual acuity before and after surgery and central macular thickness.

Results:  Over the 3 years of the study, 15/27 (56%) phakic eyes in the IVTA treated group underwent cataract surgery as compared with 2/25 (8%) initial sham-treated eyes (P < 0.001). Mean visual acuity 6 months after cataract surgery was better than at entry into the trial. Two (15%) of the eyes in the IVTA-treated group undergoing cataract surgery had a loss of >15 letters. In the IVTA-treated group, 10/15 (67%) eyes that had three or more injections had progression of posterior subcapsular cataract by ≥2 grades as compared with only 2/12 (17%) eyes that had fewer than three injections (P = 0.009).

Conclusions:  Over half of the eyes receiving IVTA injections for diabetic macular oedema required cataract surgery within 3 years. In eyes with three or more IVTA injections, two-thirds had progression of posterior subcapsular cataract. Visual outcomes after cataract surgery were generally good, although a small proportion of eyes lost greater than 15 letters over the course of the study.

Ancillary